Skip to main content
Erschienen in: hautnah 2/2022

07.04.2022 | Fallbericht

Erythroderme Psoriasis nach COVID-19-Erkrankung

verfasst von: Jeta Demiri, Miriam Abdo, PD Dr. med. Athanasios Tsianakas

Erschienen in: hautnah | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Wir präsentieren einen klinischen Fall eines Patienten mit akut exazerbierter erythrodermer Plaquepsoriasis nach einer symptomatischen Infektion mit SARS-CoV‑2. Es sind bereits unterschiedliche Faktoren bekannt, die zu einer Exazerbation der Psoriasis führen können wie Medikamente oder Infektionen mit z. B. Streptokokken. Ein Zusammenhang zwischen Psoriasis und einer Infektion mit dem neuartigen Coronavirus SARS-CoV‑2 wurde v. a. in Fallberichten beschrieben, in denen eine medikamentöse Behandlung mit z. B. Hydroxychloroquin erfolgt war, ein bekannter Trigger der Psoriasis. In der Folge gab es auch einzelne Beschreibungen einer Exazerbation nach COVID-19 ohne medikamentösen Trigger, teils auch als pustulöse Psoriasisform. Unser Artikel zeigt erstmals einen Fall einer Psoriasiserythrodermie getriggert durch eine COVID-19-Erkrankung ohne offensichtlich zusätzlich medikamentösen Auslöser.
Literatur
1.
Zurück zum Zitat Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475CrossRef Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475CrossRef
2.
Zurück zum Zitat Balak DM, Hajdarbegovic E (2017) Drug-induced psoriasis: clinical perspectives. Psoriasis 7:87–94CrossRef Balak DM, Hajdarbegovic E (2017) Drug-induced psoriasis: clinical perspectives. Psoriasis 7:87–94CrossRef
3.
Zurück zum Zitat Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated?: Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38PubMedPubMedCentral Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated?: Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38PubMedPubMedCentral
4.
Zurück zum Zitat Visser MJE, Kell DB, Pretorius E (2019) Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol 9:7CrossRef Visser MJE, Kell DB, Pretorius E (2019) Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol 9:7CrossRef
5.
Zurück zum Zitat Mallon E, Bunker CB (2000) HIV-associated psoriasis. AIDS Patient Care STDS 14:239–246CrossRef Mallon E, Bunker CB (2000) HIV-associated psoriasis. AIDS Patient Care STDS 14:239–246CrossRef
6.
Zurück zum Zitat Kutlu Ö, Metin A (2020) A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther 33(4):e13383PubMed Kutlu Ö, Metin A (2020) A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther 33(4):e13383PubMed
7.
Zurück zum Zitat Ozaras R, Berk A, Ucar DH et al (2020) Covid-19 and exacerbation of psoriasis. Dermatol Ther 33(4):e13632CrossRef Ozaras R, Berk A, Ucar DH et al (2020) Covid-19 and exacerbation of psoriasis. Dermatol Ther 33(4):e13632CrossRef
8.
Zurück zum Zitat Nasiri S, Araghi F, Tabary M et al (2020) A challenging case of psoriasis flare-up after COVID-19 infection. J Dermatolog Treat 31(5):448–449CrossRef Nasiri S, Araghi F, Tabary M et al (2020) A challenging case of psoriasis flare-up after COVID-19 infection. J Dermatolog Treat 31(5):448–449CrossRef
9.
Zurück zum Zitat Elrazi A, Abdelaziz M, Joud A et al (2021) SARS-CoV‑2 and guttate psoriasis: a case report and review of literature. Clin Case Rep 9(7):e4568 Elrazi A, Abdelaziz M, Joud A et al (2021) SARS-CoV‑2 and guttate psoriasis: a case report and review of literature. Clin Case Rep 9(7):e4568
10.
Zurück zum Zitat Buhl T, Beissert S, Gaffal E et al (2020) COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen. J Dtsch Dermatol Ges 18(8):815–825PubMedPubMedCentral Buhl T, Beissert S, Gaffal E et al (2020) COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen. J Dtsch Dermatol Ges 18(8):815–825PubMedPubMedCentral
11.
Zurück zum Zitat Buszko M, Nita-Lazar A, Park J‑H et al (2021) (2021) Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 22(4):404–411CrossRef Buszko M, Nita-Lazar A, Park J‑H et al (2021) (2021) Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol 22(4):404–411CrossRef
12.
Zurück zum Zitat Jamiolkowski D, Mühleisen B, Müller S et al (2020) SARS-CoV‑2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet 396(10251):598–599CrossRef Jamiolkowski D, Mühleisen B, Müller S et al (2020) SARS-CoV‑2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet 396(10251):598–599CrossRef
13.
Zurück zum Zitat Ragab D, Salah Eldin H, Taeimah M et al (2020) The COVID-19 Cytokine storm; what we know so far. Front Immunol 11:1446CrossRef Ragab D, Salah Eldin H, Taeimah M et al (2020) The COVID-19 Cytokine storm; what we know so far. Front Immunol 11:1446CrossRef
14.
Zurück zum Zitat Kutlu Ö, Metin A (2020) Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther 33:e13509PubMed Kutlu Ö, Metin A (2020) Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther 33:e13509PubMed
15.
Zurück zum Zitat Amerio P, Prignano F, Giuliani F et al (2020) COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol Ther 33:e13434CrossRef Amerio P, Prignano F, Giuliani F et al (2020) COVID-19 and psoriasis: Should we fear for patients treated with biologics? Dermatol Ther 33:e13434CrossRef
16.
Zurück zum Zitat Elmas ÖF, Demirbaş A, Kutlu Ö et al (2020) Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther 33(6):e13858PubMed Elmas ÖF, Demirbaş A, Kutlu Ö et al (2020) Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther 33(6):e13858PubMed
17.
Zurück zum Zitat Mahil SK, Dand N, Mason KJ et al (2021) Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 147(1):60–71CrossRef Mahil SK, Dand N, Mason KJ et al (2021) Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 147(1):60–71CrossRef
18.
Zurück zum Zitat de Wijs LEM, Joustra MM, Olydam JI et al (2021) COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data. J Eur Acad Dermatol Venereol 35(3):e173–e176PubMed de Wijs LEM, Joustra MM, Olydam JI et al (2021) COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data. J Eur Acad Dermatol Venereol 35(3):e173–e176PubMed
21.
Zurück zum Zitat Munguía-Calzada P, Drake-Monfort M, Armesto S et al (2020) Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther 34(1):e14684PubMedPubMedCentral Munguía-Calzada P, Drake-Monfort M, Armesto S et al (2020) Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther 34(1):e14684PubMedPubMedCentral
24.
Zurück zum Zitat Sachdeva M, Mufti A, Maliyar K et al (2020) Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol 83(2):579–586CrossRef Sachdeva M, Mufti A, Maliyar K et al (2020) Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol 83(2):579–586CrossRef
25.
Zurück zum Zitat Kara Polat A, Oguz Topal I, Karadag AS et al (2021) The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther 34(1):e14691CrossRef Kara Polat A, Oguz Topal I, Karadag AS et al (2021) The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther 34(1):e14691CrossRef
26.
Zurück zum Zitat Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367CrossRef Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367CrossRef
27.
Zurück zum Zitat Gravani A, Gaitanis G, Zioga A et al (2014) Synthetic antimalarial drugs and the triggering of psoriasis do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? Int J Dermatol 53(3):327–330CrossRef Gravani A, Gaitanis G, Zioga A et al (2014) Synthetic antimalarial drugs and the triggering of psoriasis do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? Int J Dermatol 53(3):327–330CrossRef
28.
Zurück zum Zitat Said A, Bock S, Lajqi T et al (2014) Chloroquine promotes IL-17 production by CD41 T cells via p38- dependent IL-23 release by monocyte-derived Langerhanslike cells. J Immunol 193(12):6135–6143CrossRef Said A, Bock S, Lajqi T et al (2014) Chloroquine promotes IL-17 production by CD41 T cells via p38- dependent IL-23 release by monocyte-derived Langerhanslike cells. J Immunol 193(12):6135–6143CrossRef
30.
Zurück zum Zitat Samotij D, Gawron E, Szczech J et al (2021) Acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with Infliximab in combination with Acitretin. Biologics 27(15):107–113 Samotij D, Gawron E, Szczech J et al (2021) Acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with Infliximab in combination with Acitretin. Biologics 27(15):107–113
31.
Zurück zum Zitat Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866CrossRef Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866CrossRef
32.
Zurück zum Zitat FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538CrossRef FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538CrossRef
Metadaten
Titel
Erythroderme Psoriasis nach COVID-19-Erkrankung
verfasst von
Jeta Demiri
Miriam Abdo
PD Dr. med. Athanasios Tsianakas
Publikationsdatum
07.04.2022
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 2/2022
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-022-00506-5

Weitere Artikel der Ausgabe 2/2022

hautnah 2/2022 Zur Ausgabe